I hope that the panel members ask tough questions of the FDA and company. Safety must be confirmed. If these criteria are met, then I expect a favorable recommendation and quick approval for compassionate access. I have never believed in waiting for peer reviews or the next scheduled association meeting of neurologist to give a blessing to a drug. This process should not be delayed because of this ego shadow protocol.
Advisory panels are public forums with membership of scientific experts.
These Independent panel experts and FDA Internal experts must sanction the validity of the data. Once advisory board recommendations are made and full public disclosure so ALS patients and their physicians can make informed decisions. I pray that this meeting addresses all concerns and validates some measure of effectiveness. Good luck to us all. One of the theories surrounding ALS is the glutamate impact on this disease.